SLDB Key Statistics, Chart & Performance
The current stock price of SLDB is 5.21 USD. In the past month the price decreased by -3.34%. In the past year, price increased by 3.17%.
SLDB Latest News, Press Relases and Analysis
SLDB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About SLDB
Company Profile
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Company Info
SOLID BIOSCIENCES INC
500 Rutherford Avenue, 3rd Floor
Charlestown MASSACHUSETTS 02139 US
CEO: Ilan Ganot
Employees: 100
Phone: 16173374680
SOLID BIOSCIENCES INC / SLDB FAQ
What does SLDB do?
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
What is the current price of SLDB stock?
The current stock price of SLDB is 5.21 USD. The price decreased by -4.05% in the last trading session.
What is the dividend status of SOLID BIOSCIENCES INC?
SLDB does not pay a dividend.
What is the ChartMill rating of SOLID BIOSCIENCES INC stock?
SLDB has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for SLDB stock?
19 analysts have analysed SLDB and the average price target is 15.47 USD. This implies a price increase of 196.93% is expected in the next year compared to the current price of 5.21.
SLDB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SLDB. When comparing the yearly performance of all stocks, SLDB turns out to be only a medium performer in the overall market: it outperformed 41.86% of all stocks.
SLDB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLDB. SLDB has a great financial health rating, but its profitability evaluates not so good.
SLDB Financial Highlights
Over the last trailing twelve months SLDB reported a non-GAAP Earnings per Share(EPS) of -2.49. The EPS increased by 18.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.02% | ||
| ROE | -76.69% | ||
| Debt/Equity | 0 |
SLDB Forecast & Estimates
19 analysts have analysed SLDB and the average price target is 15.47 USD. This implies a price increase of 196.93% is expected in the next year compared to the current price of 5.21.